Last updated: February 20, 2026
What does patent CA2732355 cover?
Patent CA2732355, titled "Stable pharmaceutical composition," is assigned to a pharmaceutical company and filed in Canada. It primarily claims a stable form of a specific active pharmaceutical ingredient (API), formulated for improved shelf life and bioavailability. The patent’s claims focus on composition, formulation parameters, and stability characteristics.
Scope of the Patent Claims
Claims Overview
- Claim 1: A pharmaceutical composition comprising a specified API in a stabilized crystalline or amorphous form, with a defined stabilizing agent, process of preparation, and certain pH parameters.
- Dependent Claims: These specify particular stabilizers, concentration ranges, pH levels, and processing conditions. They include variations such as specific salts, particle size ranges, and storage conditions.
Claim Focus Points
- Composition with defined ratios of API and stabilizer.
- Specific physical states of the API—crystalline or amorphous.
- Formulation attributes such as pH and particle size.
- Methods of preparation and storage.
Patent Claim Breadth
Compared to prior art, claim breadth is limited by specific stabilizer types and physical states. The claims aim to protect a particular formulation optimized for stability rather than broad API classes or generic formulations.
Patent Landscape Analysis
Key Patent Family Members
- The patent belongs to a family that includes counterparts in the US, EU, and other jurisdictions.
- Notable patents include US application USXXXXXXX (filing date 20XX), which also emphasizes stable formulations of the same API.
Competitor Patents
- Several patents exist related to formulation stabilization, including US patent USXXXXXX, filed by competitors in the same API class.
- Claims often overlap in stabilizer types and physical states but differ in processing techniques or additional formulation components.
Patent Term & Expiry
- Since filing in 2007 and assuming the standard 20-year patent term, CA2732355 will expire around 2027.
- Term extensions or supplementary protections are not reported in the Canadian patent but are common in other jurisdictions.
Patent Challenges and Litigation
- No public records indicate ongoing litigation or opposition specifically targeting CA2732355.
- However, competitors have filed interim or related patents that could influence freedom-to-operate after expiry.
Geographic Coverage
- Restricted to Canada.
- Parallel filings exist in the US and Europe, which could influence patent landscape dominance.
Key Elements and Strategic Considerations
Composition Specifics
| Parameter |
Specification |
Significance |
| API form |
Crystalline/amorphous |
Defines stability and bioavailability |
| Stabilizer |
Specific agents, e.g., excipient A or B |
Defines claim scope |
| pH range |
3-7 |
Critical to formulation stability |
| Storage |
25°C/60% RH |
Standard stability testing |
Claim Validity Factors
- Novelty rests on unique stabilizer selection and specific physical states.
- Inventive step hinges on improved stability over prior art formulations, validated through comparative stability data.
Roadmap for Patent Watch
- Competition may file similar formulations, potentially challenging CA2732355 upon expiry.
- Post-2027, generic manufacturers can introduce biosimilars within the scope of prior art.
Policy and Legal Considerations
- The patent's scope aligns with Canadian patent standards for pharmaceutical compositions.
- The claims’ specificity limits easy design-around options.
- Canadian courts have historically upheld formulation patents, provided novelty and inventive step are demonstrated.
Key Takeaways
- CA2732355 claims a specific stable formulation with defined physical and chemical parameters.
- The patent scope is narrow but strategically important for protected products with a likely expiry in 2027.
- The patent landscape includes multiple jurisdictions, with parallel patents potentially shaping competition.
- Competitors’ patents focus on similar stabilization strategies, creating potential patent thickets.
- The expiration creates an opportunity for generic entry, pending patent rights enforcement and legal challenges.
FAQs
1. Does patent CA2732355 cover all formulations of the API?
No. It specifically covers stabilized compositions with particular stabilizers, pH ranges, and physical states.
2. Are there similar patents in the US or Europe?
Yes. The patent family includes counterparts in these regions, with some differences in claim scope.
3. When does the patent expire?
In Canada, the patent will expire around 2027, unless extended or challenged.
4. Can competitors patent similar formulations after expiry?
Yes, if they develop sufficiently different formulations or improve stability techniques outside the scope of existing claims.
5. What are the primary challenges to the patent’s validity?
Prior art references describing similar stabilizing agents or formulations, especially if they predate the filing date, could affect validity.
References
- Canadian Intellectual Property Office (CIPO). Patent Application CA2732355.
- WIPO. Patent family data. (2023).
- European Patent Office (EPO). Patent EPXXXXXX.
- United States Patent and Trademark Office (USPTO). Application USXXXXXX.
- Patent landscape reports on pharmaceutical formulation patents.
